The convergence is occurring against a widening public-health backdrop. The review reports that an estimated 2.4 million people aged 12 or older in the United States reported past-year methamphetamine use in 2024, while self-reported concurrent methamphetamine and fentanyl use nearly doubled between 2011 and 2017. Fentanyl positivity among methamphetamine-positive urine samples rose from 0.9% to 7.9% between 2013 and 2018. Because methamphetamine is sometimes intentionally mixed with fentanyl, people who believe they are using only a stimulant may be exposed to a potent opioid without knowing it, increasing the danger of overdose and other adverse outcomes.

Methamphetamine and fentanyl act through distinct but overlapping systems. The stimulant is highly lipophilic, enters the brain rapidly and has a substantially longer half-life than cocaine—about 12 hours in the cited pharmacological literature. It acts at trace amine-associated receptor 1 and disrupts vesicular monoamine transporter 2, producing marked increases in extracellular dopamine, noradrenaline and serotonin. These changes in mesocorticolimbic circuitry support reinforcement, cue learning and incentive salience. Repeated exposure can also sensitize behavioral responses, meaning that a fixed dose produces progressively stronger locomotor effects, and can alter brain systems associated with reward seeking and anxiety-like states.

Fentanyl, meanwhile, is a highly lipid-soluble opioid that binds with high efficacy to μ-opioid receptors. These Gi/o-coupled receptors reduce neuronal excitability and neurotransmitter release when activated. In the ventral tegmental area, where dopamine neurons project toward the nucleus accumbens and other reward-related regions, μ-opioid receptor activation on inhibitory GABAergic neurons can disinhibit dopamine cells. Acute fentanyl exposure therefore increases dopaminergic activity in circuits that participate in reward. Its high potency, rapid onset and relatively long half-life—three to seven hours—help explain why it can support both powerful reinforcement and substantial dependence.

Rodent studies show that both drugs readily become highly reinforcing. Methamphetamine-taking animals escalate their intake over repeated sessions, develop persistent preference for drug-paired environments and reinstate drug seeking after exposure to drug cues, stressors or a priming injection. Chronic exposure also produces withdrawal-related reductions in motivation for natural rewards and increases in anxiety-like behavior. Fentanyl produces a similar broad addiction profile: rodents rapidly acquire conditioned preference for fentanyl-paired locations, self-administer escalating amounts and reinstate seeking after extinction. Withdrawal from either drug can include stress, agitation, anxiety-like symptoms, anhedonia and reduced motivation, potentially supporting continued use through negative reinforcement as well as positive reinforcement.

The direct evidence for combined exposure points to a behavioral interaction rather than merely the sum of two separate drug effects. In one conditioned place-preference experiment in adult male rats, doses of methamphetamine and fentanyl that were ineffective when given separately successfully produced preference and reinstatement when administered together. In concurrent-access studies, rats adjusted their responses according to the relative reinforcing value of methamphetamine and fentanyl, showing that the drugs could function as substitutes under some conditions. Another study found that rats did not reduce their inter-infusion interval as fentanyl doses increased during combined self-administration to the same degree seen with fentanyl alone, resulting in greater overall intake. These findings indicate changes in reinforcement, but their magnitude depends on dose and experimental schedule.

Combined exposure may also join the motivational pathways associated with the two drugs. Rats trained to self-administer methamphetamine and fentanyl through concurrent access later showed cross-reinstatement after extinction: fentanyl-associated cues or fentanyl priming injections restored methamphetamine seeking, while methamphetamine-associated cues or priming injections restored fentanyl seeking. The result suggests that repeated co-exposure can create overlapping associations, allowing one substance or its cues to trigger pursuit of the other. The experiment was conducted in rats, and the finding cannot by itself establish how the same processes operate in human relapse.

Neurochemical findings are similarly intriguing but not yet conclusive. Methamphetamine-fentanyl self-administration produced significant reductions in dopamine release and reuptake in the nucleus accumbens, with a more pronounced hypodopaminergic state in males exposed to the combination than in animals receiving methamphetamine alone. Measurements were made roughly 22 hours after the final self-administration session, outside the acute drug effects, suggesting compensatory adaptations after repeated exposure rather than the immediate neurochemical response to intoxication. The contrast with evidence that acute μ-opioid receptor activation increases dopamine is not necessarily contradictory: intoxication and withdrawal-like states may involve different phases of mesolimbic signaling. A state that feels highly rewarding during exposure may therefore be followed by diminished responsiveness to ordinary rewards.

μ-opioid receptors are the leading candidate mechanism because they sit at the intersection of the two drugs’ reward circuitry. Blocking these receptors with naltrexone attenuates methamphetamine-induced conditioned place preference, behavioral sensitization and cue-induced craving in animal studies, while genetic deletion reduces methamphetamine sensitization in mice. Human studies likewise found that naltrexone reduced cue-induced craving and subjective hedonic responses to methamphetamine. Opioid antagonism also reduces methamphetamine-related drug seeking in some rodent paradigms. However, these experiments did not directly test fentanyl-methamphetamine combinations. Studies with morphine or heroin offer additional support for stimulant-opioid interactions, but their pharmacology differs from fentanyl, and sequential exposure cannot establish the consequences of simultaneous use.

Human reports add another dimension but remain limited by variable doses, routes and timing. People who use psychostimulants with opioids often describe the combination as balancing two drugs: the stimulant may counter opioid-related sedation, while the opioid may reduce stimulant-associated anxiety or restlessness. Such accounts suggest that both enhanced pleasure and relief from aversive states can motivate co-use. Clinical studies also associate stimulant-opioid use with more anxiety, depression, impulsivity, anhedonia and psychotic symptoms than stimulant use alone, but those findings do not prove that withdrawal from the combination is more severe than withdrawal from either constituent drug. Direct evidence on withdrawal after repeated methamphetamine-fentanyl exposure is particularly sparse.

The review’s central conclusion is therefore both promising and restrained: existing evidence supports a synergistic addiction potential for concurrent methamphetamine and fentanyl use, but the specific mechanism and full behavioral consequences remain under-examined. The most important research gaps are systematic dose-response comparisons, experiments separating simultaneous from sequential exposure, direct characterization of spontaneous and precipitated withdrawal, and studies that manipulate μ-opioid signaling during combined exposure. Measuring neural activity alongside dopamine release would also help distinguish changes in ventral tegmental circuit function from downstream alterations in the nucleus accumbens. Until those studies fill the gaps, the evidence supports concern about the combination, not a complete causal map of how it alters the human brain or whether every dose and pattern of use produces the same effect.

Subject of Research: Behavioral and neurobiological consequences of concurrent methamphetamine and fentanyl use

Article Title: Separate and concurrent use of methamphetamine and fentanyl: behavioral and neurobiological consequences

Article References: Madden, J. T., Clark, B. J., Hamilton, D. A., & Pentkowski, N. S. (2026). Separate and concurrent use of methamphetamine and fentanyl: behavioral and neurobiological consequences. Frontiers in Behavioral Neuroscience, 20, Article 1966221. https://doi.org/10.3389/fnbeh.2026.1966221

Image Credits: AI Generated

DOI: 10.3389/fnbeh.2026.1966221

Keywords: methamphetamine, fentanyl, polydrug use, addiction, dopamine signaling, μ-opioid receptors, conditioned reward, drug seeking, rodent studies, withdrawal, Separate, concurrent

The consequences of leaving this pain untreated are not trivial. In extremely preterm infants, those born at twenty-eight weeks of gestation or earlier, exposure to high numbers of noxious stimuli has been associated with disruption of thalamocortical development, the intricate wiring process that connects the brain’s sensory relay station to its outer cortex. Follow-up studies of these children have linked early pain exposure to unfavorable cognitive, sensory, and behavioral outcomes years later. Care teams do what they can with gentler tools: topical anesthetics, oral sucrose, skin-to-skin contact, swaddling, and non-nutritive sucking all help for minor procedures. But for unsettled, endotracheally intubated, hemodynamically unstable infants, or those undergoing surgery, stronger medicine is required, typically morphine, a natural opioid, or fentanyl, a synthetic, lipophilic phenylpiperidine opioid agonist.

Among neonates, fentanyl has largely displaced morphine as the analgesic of choice, and for understandable pharmacological reasons. It causes less cardiovascular instability and fewer episodes of hypotension, binds with higher specificity to mu-opioid receptors, and is fifty to four hundred times more potent than morphine, which acts as a non-specific opioid receptor agonist. Its efficacy in blunting the surgical stress response was demonstrated decades ago in a randomized trial of preterm babies undergoing ligation of a patent ductus arteriosus, a landmark study that helped establish opioid anesthesia for the tiniest surgical patients. But effectiveness comes with a shadow. Opioid exposure in the NICU has been associated with smaller cerebellar volumes, cerebellar hemorrhages, and altered long-term neurodevelopment. Earlier work suggested that infants exposed to greater numbers of painful experiences who received morphine for more than seven days showed lower cognition, while shorter exposures had less negative impact. A longitudinal study of 936 extremely preterm infants born at twenty-four to twenty-seven weeks of gestation found that prolonged exposure, longer than seven days, to morphine, fentanyl, midazolam, or lorazepam was associated with adverse effects on two-year neurodevelopmental outcomes, reflected in lower scores on the Bayley Scales of Infant Development, Third Edition. A retrospective study of infants born between twenty-three and thirty-two weeks similarly found that cumulative opioid exposure in the NICU was negatively associated with cognitive and motor development at three years of adjusted age. These findings raise an uncomfortable clinical dilemma: how to manage pain effectively while minimizing the adverse outcomes that the analgesics themselves may carry.

Into this dilemma steps an unexpected player, one that until recently had little place in conversations about neonatal analgesia: the gut microbiome. The community of trillions of microbes colonizing the infant intestine is increasingly recognized as a critical regulator of developmental processes far beyond digestion, shaping immune responses, metabolism, and hormonal signaling in both the gut and remote organs, including the brain. This microbiome-gut-brain axis has become one of the most active frontiers in developmental biology, and the early weeks of life represent a uniquely sensitive window during which microbial colonization patterns can have lasting consequences.

Preterm infants, it turns out, start life with a microbial handicap. Compared with their term-born counterparts, they carry gut microbiomes characterized by lower diversity and a conspicuous lack of Bifidobacterium species, beneficial members of the phylum Actinobacteriota that normally dominate the healthy infant gut. Their microbial communities are also particularly vulnerable to the hospital environment, being seeded less by maternal microbes and more by whatever organisms circulate in the intensive care unit. Given all of this, a pressing question arises: what happens to this fragile ecosystem when the infant is repeatedly dosed with one of the most potent opioids in clinical use? Until now, the effect of opioid exposure on the early-life microbiome had not been well studied.

A new investigation by David and colleagues, published in Pediatric Research and accompanied by a commentary from researchers at the University of Calgary, set out to answer exactly that question. The study leveraged the prospective Microbiome analysis in Neonatal Development, or MIND, cohort, which enrolled 250 infants born at less than thirty-seven weeks of gestation. For the fentanyl analysis, the researchers compared twenty-two infants with no fentanyl exposure, whose mean gestational age was thirty-one weeks, against forty-six infants who received the drug, whose mean gestational age was twenty-seven weeks. The team collected a wide range of clinical covariates, including sociodemographic information, mode of delivery, sex, postmenstrual age, length of NICU stay, intrauterine and extrauterine growth differences, enteral feeding patterns, antibiotic use, and major clinical morbidities, all of which are known to independently shape the infant microbiome.

What distinguishes this study technically is the depth of its microbiological and statistical toolkit. Rather than relying on a single sequencing approach, the researchers deployed 16S rRNA gene sequencing to profile microbial composition, deep shotgun metagenomic sequencing to resolve the functional potential of the microbial communities at the level of individual genes, and fecal metabolomics to measure the actual chemical products of gut microbial metabolism. This three-pronged strategy allowed them to dissect not just which microbes were present, but what those microbes might be doing, and how their metabolic output differed between fentanyl-exposed and unexposed infants. On the neurodevelopmental side, outcomes were assessed at two years of age using the Bayley Scales of Infant Development, Third Edition, and again between three and eight years of age using the Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition, providing both early and later cognitive measures. Statistical analysis employed linear regression models and mixed binomial regression models to test the relationship between fentanyl exposure and microbiome features while adjusting for the extensive panel of clinical covariates.

The headline finding is striking: fentanyl exposure was associated with measurable alterations in the gut microbiome, and these microbial changes appeared to be linked to adverse cognitive outcomes in the preterm children when they were assessed at two to eight years of age. In other words, the study suggests that the drug given to protect the developing brain from pain may, through the intermediary of the gut’s microbial ecosystem, contribute to the very neurodevelopmental harms clinicians have been trying to understand. The commentary’s authors, Chunlong Mu, Kamran Yusuf, and Shabih U. Hasan of the Cumming School of Medicine at the University of Calgary, were careful to commend the study’s rigor, particularly the painstaking effort to account for a large number of maternal and infant variables in the statistical analyses, a step many microbiome studies skip at their peril.

Yet the same commentators, and the study’s own design, demand caution before drawing firm conclusions. The sample size was small, with only sixty-eight infants in the final analysis, and the complexity of confounding variables in this population is formidable. Fentanyl-exposed infants were, on average, born four weeks earlier than unexposed infants, and greater prematurity independently predicts both altered microbiome development and worse neurodevelopmental outcomes. Even the most sophisticated regression models cannot fully disentangle such entangled factors. As a result, a direct causal link between fentanyl exposure and neurodevelopmental outcomes cannot be established from this study. The association between the drug, the microbiome, and later cognition is real and intriguing, but the direction of causality and the magnitude of any true drug effect remain open questions.

What the study does establish is a compelling new framework for thinking about neonatal analgesia. If opioids reshape the preterm gut microbiome, and if those microbial shifts contribute to cognitive outcomes years later, then the microbiome becomes a modifiable target, a potential mediator whose effects might be buffered by probiotics, tailored nutrition, or more judicious dosing strategies. It also adds urgency to efforts to reduce opioid exposure where possible, expanding non-pharmacological comfort care and reserving sedation for infants who truly need it. The research was supported by a grant from the Canadian Institutes of Health Research, and its authors declare no competing interests. For the thousands of infants who pass through neonatal intensive care each year, and for the clinicians who must balance the immediate imperative of pain relief against the long-term imperative of healthy brain development, this work opens a promising and unexpected avenue: protecting the developing mind by tending the garden of microbes in the gut.

Subject of Research: The association between early-life fentanyl exposure, gut microbiome alterations, and neurodevelopmental outcomes in preterm infants

Article Title: Early-life fentanyl exposure, microbiome-brain axis and neurodevelopment

Article References: Mu, C., Yusuf, K., & Hasan, S. U. (2026). Early-life fentanyl exposure, microbiome-brain axis and neurodevelopment. Pediatric Research. https://doi.org/10.1038/s41390-026-05424-3

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05424-3

Keywords: fentanyl, preterm infants, gut microbiome, microbiome-gut-brain axis, neonatal intensive care, neurodevelopment, neonatal pain, opioids, shotgun metagenomics, Bayley Scales, Pediatric Research, Bifidobacterium

Xylazine is a sedative approved for veterinary use in animals such as horses and cattle, but it has never been approved for human use. Over the past several years, it has increasingly infiltrated the fentanyl supply in the United States, producing what researchers have described as an emerging fentanyl-xylazine syndemic. One of its most alarming hallmarks is the development of severe skin wounds and ulcers, often at injection sites or elsewhere on the body, that can be disfiguring and difficult to heal. Public health agencies have struggled to raise awareness of this phenomenon, which remains poorly understood even among many clinicians.

The Pitt, a medical drama set in a Pittsburgh emergency department, devoted an episode to a patient presenting with xylazine-associated skin wounds, depicting the characteristic lesions and the clinical challenges they pose. Zhu’s report leveraged Google Trends, the publicly available search analytics platform, to quantify whether the broadcast translated into measurable public curiosity. The approach follows a growing body of research using internet search data as a real-time barometer of health information-seeking behavior, capturing the moment when a media event propels a previously obscure term into mainstream consciousness.

The findings add to a well-documented pattern in which popular media drives spikes in health-related searches. Previous studies have shown that the release of the television series The White Lotus was followed by increased internet searches for lorazepam, the sedative featured in the show. The Netflix series 13 Reasons Why was associated with increased youth suicides in the United States, a finding that triggered intense debate about media portrayals of suicide. The release of the film Barbie produced a measurable rise in online search interest in gynecologists. Even the Katie Couric effect, named after the television anchor’s on-air colonoscopy, demonstrated that celebrity-driven media events can increase the use of colon cancer screening, while Angelina Jolie’s editorial about her BRCA gene testing was followed by observable changes in testing and mastectomy rates.

What distinguishes the xylazine case is the nature of the subject matter. Unlike colonoscopy or genetic testing, xylazine is not a medical intervention that viewers might seek out; it is a contaminant in the drug supply associated with severe harm. The search surge therefore likely reflects a mix of motives: viewers trying to understand what they had just seen, people who use drugs seeking information about a substance they may encounter, clinicians looking up an unfamiliar presentation, and members of the public grappling with the visceral imagery of xylazine wounds. Each of these audiences represents a potential point of intervention for public health communication.

The technical logic of the study rests on Google Trends data, which normalizes search volume on a relative scale from 0 to 100, allowing researchers to compare interest before and after a specific event. By anchoring the analysis to the episode’s air date and examining the trajectory of searches for xylazine and related terms, the report could isolate the temporal association between the broadcast and the surge in queries. This methodology, while observational, has become a standard tool in infodemiology, the study of information patterns on the internet as they relate to public health. Its strength lies in timeliness and scale; its limitation is that search volume reveals attention, not intent or outcome.

That distinction matters for interpretation. A spike in searches does not by itself demonstrate that viewers changed their behavior, sought treatment, or adopted safer practices. It does, however, demonstrate a window of heightened receptivity. Public health researchers have long argued that such windows are precious and perishable: when a media event makes an obscure term like xylazine momentarily salient, the opportunity to deliver accurate, actionable information is greatest in the hours and days that follow. If health agencies are not prepared to meet that attention with accessible content, the moment passes and the information vacuum may be filled by less reliable sources.

The report also underscores the evolving relationship between entertainment media and drug-related health literacy. Fictional portrayals of drug use have historically been criticized for glamorization or inaccuracy, but The Pitt’s depiction of xylazine wounds appears to have functioned as an unintentional public health signal, prompting audiences to learn about a phenomenon that official campaigns have struggled to communicate. This raises questions about whether producers of medical dramas might deliberately coordinate with public health authorities when depicting emerging drug threats, ensuring that accurate information is available at the exact moment audience curiosity peaks. The precedent of the Katie Couric effect suggests that media-driven attention can translate into concrete health behavior when paired with credible guidance.

For researchers, the study contributes to a growing literature on media effects in the digital age, sitting at the intersection of media reception studies, media psychology, and drug policy. For clinicians, it is a reminder that patients may arrive with questions shaped by what they watched the night before, and that familiarity with xylazine’s clinical presentation, including its characteristic wounds and its resistance to naloxone reversal because it is not an opioid, is increasingly relevant in emergency settings. For the public, the episode and the ensuing search surge illustrate how a single hour of television can briefly illuminate one of the most disturbing developments in the ongoing overdose crisis.

The broader lesson is about the speed and scale of modern attention. In an era when streaming platforms deliver episodes to millions of viewers simultaneously, the lag between a media event and a measurable public response has collapsed to nearly zero. Zhu’s report, published as a concise research report in the Journal of General Internal Medicine, captures that collapse in real time for a drug that most Americans had never heard of a few years ago. Whether the surge in searches translates into lasting awareness, safer behavior, or better clinical recognition remains an open question, but the study makes clear that the operating room for public health messaging now opens the moment the credits roll.

Subject of Research: Media-driven online search interest in xylazine after a television drama depicted its associated skin wounds

Article Title: Online Searches for Xylazine Following The Pitt Episode Featuring Xylazine-Associated Skin Wounds

Article References: Zhu, D. T. (2026). Online Searches for Xylazine Following The Pitt Episode Featuring Xylazine-Associated Skin Wounds. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10943-0

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10943-0

Keywords: xylazine, The Pitt, Google Trends, fentanyl, television drama, public health, infodemiology, skin wounds, opioid crisis, media effects, health communication, Journal of General Internal Medicine

The research team, led by scientists from the U.S. FDA’s National Center for Toxicological Research along with collaborators at Arkansas State University and the University of Arkansas at Little Rock, turned to the FDA Adverse Event Reporting System, or FAERS, a database that collects spontaneous reports of suspected drug-associated adverse events from healthcare professionals, patients, and manufacturers. The sheer scale of the data presented formidable challenges: the team retrieved approximately 18 million adverse event reports spanning from the first quarter of 2004 through the third quarter of 2024, containing over 342 million drug-adverse event pairs. Because the drug name field in FAERS is captured as free text without validation against a controlled vocabulary, a single active ingredient may appear under proprietary names, generic names, salt variants, combination-product names, foreign trade names, and misspellings. The researchers used RxNorm, a standardized nomenclature for clinical drugs, to normalize these variants and consolidate them to common identifiers, a prerequisite for valid disproportionality analysis.

To detect statistically meaningful safety signals from this vast dataset, the team applied the Empirical Bayes Geometric Mean method, a Bayesian approach conceptually similar to the Proportional Reporting Ratio but incorporating shrinkage and stratification. This method adjusts disproportionality scores toward the null, particularly when data include small counts, thereby reducing the influence of spurious high values and minimizing false positives. The EBGM approach is known as the most conservative of popular signal detection algorithms, offering a more stable estimate of the relative reporting rate of an event for a particular product compared to all other events in the database. The researchers identified potential safety signals when the lower 95% confidence limit of the EBGM, referred to as EB05, exceeded one and the drug-adverse event pairs existed no less than three times. Cardiovascular-related Preferred Terms from the Medical Dictionary for Regulatory Activities, or MedDRA, were then applied to filter the signals to those involving cardiac disorders and vascular disorders.

The results revealed a striking hierarchy of cardiovascular risk among the opioids. Fentanyl was the most-reported prescription opioid, with 32,069 cardiovascular adverse event pairs detected, followed by oxycodone, tramadol, and morphine. After disproportionality analysis, fentanyl still had the largest number of signals of disproportionate reporting, or SDRs, at 22,866, representing 71.30% of its reported cardiovascular pairs and including 117 unique cardiovascular adverse events. Morphine, tramadol, and hydromorphone followed. Notably, although remifentanil’s cardiovascular adverse event pairs made up only 1.47% of the total reported pairs in the dataset, its SDR-to-pair ratio was the highest at 90.32%, with sufentanil close behind at 89.71% and pentazocine at 68.28%, indicating that these opioids, despite lower reporting volumes, showed disproportionately concentrated cardiovascular safety signals.

Among the specific cardiovascular adverse events, hypotension was the most frequently identified signal, with 7,107 occurrences, followed by cardiac arrest with 5,436, tachycardia with 3,600, cardio-respiratory arrest with 3,480, and hypertension with 3,358. Fentanyl and morphine were the primary contributors to hypotension, cardiac arrest, and tachycardia, together representing over 70% of each of these events. Fentanyl was identified as a major contributor in four of the five top cardiovascular events, highlighting its potent cardiovascular risk profile among all prescription opioids examined. Codeine and hydromorphone accounted for the largest share of hypertension signals. Although remifentanil and sufentanil were not among the dominant contributors to any individual event, both opioids appeared consistently across all five, suggesting broad cardiovascular risk profiles that warrant cautious consideration despite their relatively lower reporting volumes.

Each of the 15 opioids also displayed distinctive cardiovascular safety signatures. Methadone showed a profile dominated by torsade de pointes, a life-threatening arrhythmia, ranking among its top three signals. Oxycodone’s signals were notably concentrated in pericarditis, accounting for 43.9% of its total cardiovascular signals, with codeine showing a similar but less pronounced pattern at 19.0%. Hydromorphone’s profile was distinct, dominated by cardiogenic shock, ventricular fibrillation, and thrombosis. Buprenorphine’s top signals were tachycardia and cardio-respiratory arrest, each exceeding 28% of its total cardiovascular signals. Tapentadol showed signals including hypertensive crisis and cardiac failure. These drug-specific patterns suggest that cardiovascular risk labeling could be refined to reflect the unique safety profiles of individual opioids rather than treating the class as homogeneous.

To uncover latent relationships among the opioids based on their shared cardiovascular adverse event profiles, the researchers turned to unsupervised machine learning approaches. Network analysis constructed a bipartite graph of drug-adverse event associations, then projected it into a one-mode network of opioids, where connections between drug nodes represented the total number of shared cardiovascular events. Hierarchical clustering applied the Jaccard distance, a metric quantifying dissimilarity between drug pairs based on the cardiovascular events they share, to group opioids into clusters using the average linkage method. The network analysis revealed that fentanyl, morphine, remifentanil, sufentanil, hydrocodone, and methadone had the biggest numbers and thickest lines connecting each other, with the strongest associations found between fentanyl and morphine, sharing 51 cardiovascular events, and between fentanyl and remifentanil, sharing 48. Interestingly, oxycodone had the fewest shared cardiovascular events among the 15 opioids despite having 4,813 identified signals, suggesting it is associated with a more distinct and less overlapping set of cardiovascular signals.

The hierarchical clustering divided the 15 opioids into two major clusters. Cluster A comprised only hydromorphone and oxycodone, which share a highly similar but distinctly different cardiovascular profile compared to all other opioids. Cluster B comprised the remaining 13 opioids, within which fentanyl, remifentanil, and sufentanil grouped most closely together, with remifentanil and sufentanil forming the tightest pair before joining fentanyl and then morphine. Hydrocodone and tramadol also clustered closely, while codeine and tapentadol formed their own sub-pair along with buprenorphine, oxymorphone, and pentazocine. To further quantify pairwise similarities, the researchers computed a Pearson correlation matrix across the counts of signals of disproportionate reporting for all cardiovascular events for each opioid. The R code for this correlation analysis was generated with the assistance of a large language model, Claude, developed by Anthropic, and then reviewed and verified by the authors, who take full responsibility for the accuracy and integrity of the results.

The correlation heatmap identified exceptionally strong pairwise similarities. Pentazocine and buprenorphine showed a correlation of 0.96, oxymorphone and methadone showed 0.92, and remifentanil and sufentanil showed 0.91, confirming the fentanyl-remifentanil-sufentanil-morphine cluster as the most internally coherent cardiovascular risk profiling group in the dataset. Given that fentanyl, remifentanil, and sufentanil are all synthetic opioids in the phenylpiperidine class, this observation may reflect their shared structural class and pharmacologic properties, including potent μ-opioid receptor agonism and common clinical use in perioperative and critical-care settings where hemodynamic events such as hypotension, bradycardia, and cardiac arrest are frequently observed and reported. However, the researchers caution that the tight clustering may partly reflect confounding by shared reporting context rather than intrinsic drug effects, and that correlations among agents such as oxymorphone, methadone, pentazocine, and buprenorphine may arise from overlapping patient populations and prescribing patterns as much as from pharmacological similarity.

Notably, when the machine learning analyses were applied exclusively to cardiovascular signals, the resulting opioid relationships differed from those generated using whole adverse event profiles in the team’s previous work. Fentanyl and hydromorphone, which showed strong associations when all adverse events were considered, had few shared cardiovascular events and showed distance in the clusters when the analysis was limited to cardiovascular signals alone. This difference highlights the importance of organ-focused pharmacovigilance, suggesting that condition-specific safety analyses can uncover hidden risk relationships that broader assessments mask. The researchers emphasize that FAERS is a passive surveillance system subject to substantial reporting bias, underreporting, and varied reporting quality, and that disproportionality metrics cannot be used to estimate incidence, absolute risk, or causality. The analyses also cannot adjust for confounding factors such as comorbidities, concomitant medications, dose, route, and duration of therapy. Nevertheless, the findings highlight the need for targeted cardiovascular risk assessment and monitoring, such as electrocardiogram screening with methadone or cardiovascular monitoring during fentanyl administration, and support more refined prescribing practices, opioid safety labeling, and regulatory decision-making to mitigate prescription opioid-related cardiovascular harm.

Subject of Research: Cardiovascular safety signals of prescription opioids analyzed from two decades of FAERS data using machine learning

Article Title: Two decades of prescription opioid-related cardiovascular safety signals: a FAERS-based pharmacovigilance study using machine learning

Article References: Ma, L., Berryhill, J., Ihrie, J., Chen, R., Lyn-Cook, B., Rogers, P., Ge, W., Wu, N., Hong, H., Tong, W., & Zou, W. (2026). Two decades of prescription opioid-related cardiovascular safety signals: a FAERS-based pharmacovigilance study using machine learning. Frontiers in Drug Safety and Regulation, 6, Article 1898403. https://doi.org/10.3389/fdsfr.2026.1898403

Image Credits: AI Generated

DOI: 10.3389/fdsfr.2026.1898403

Keywords: prescription opioids, cardiovascular adverse events, FAERS, pharmacovigilance, machine learning, Empirical Bayes, drug safety, fentanyl, methadone, network analysis, decades, prescription

Dustin Kee of Johns Hopkins University School of Medicine, John Buyske and Ashish Thakrar of the University of Pennsylvania Perelman School of Medicine argue that the urine drug test has been absorbed into routine clinical practice without the interpretive guardrails applied to virtually every other diagnostic tool. Used both as a targeted diagnostic and, at the population level, as a screen, the technology behind most UDTs is an immunoassay, a method that detects antibody binding to an entire drug class and rapidly returns a presumptive positive or negative result. That speed and binary simplicity, the authors write, confer a false sense of precision that masks serious limitations: immunoassays cross-react with commonly prescribed medications, miss many of the synthetic compounds that now dominate the unregulated drug supply, and can remain positive well beyond any clinically relevant window of intoxication.

The analytical logic explains why. An immunoassay does not identify a specific molecule; it recognizes structural features shared across a class of compounds. Anything in the urine that mimics those features can trigger a positive signal, whether or not the patient took the drug in question. Conversely, if the target compound lacks the structural features the antibody was designed to detect, the test returns a negative even when the drug is present. Results therefore must be interpreted against the clinical history, the physical examination for signs of intoxication or withdrawal, and basic pharmacology, with confirmatory mass spectrometry when precision matters. In practice, the authors observe, the UDT alone frequently drives management decisions.

The historical trajectory helps explain how medicine arrived here. The immunoassay-based UDT rose to prominence in the early 1970s, first through Operation Golden Flow, the mass screening program for returning Vietnam War veterans, and then through Nixon-era federal methadone regulations that mandated routine urine testing. At the time, the drug supply consisted largely of a few plant-derived substances such as heroin, opium, and cocaine, a narrow and stable set of targets to which immunoassays were reasonably well suited, in an era when fewer medications existed to cross-react and confound results. Workplace screening later became embedded in occupational health and Department of Transportation protocols, and only afterward migrated into routine clinical medicine, adopted without adequate refinement or clinician training and applied to diagnostic questions it was never designed to answer.

The chemistry of modern confounding is remarkable. Bupropion, an antidepressant, and labetalol, a blood pressure medication, both cross-react with amphetamine immunoassays. Dextromethorphan, the ubiquitous cough suppressant, can produce a false positive for phencyclidine, and the antidepressant sertraline can mimic benzodiazepines. False negatives are just as systematic. Fentanyl, now the dominant opioid in the unregulated supply, along with methadone and buprenorphine, the cornerstone treatments for opioid use disorder, are synthetic or semi-synthetic compounds that the standard opiate immunoassay does not detect at all, because that assay specifically targets plant-based opiates derived from the poppy. Benzodiazepine immunoassays, optimized for diazepam, perform poorly for clonazepam and many other drugs in the class, as well as for designer benzodiazepines such as bromazolam increasingly encountered in the illicit market. Detection windows also stretch far beyond intuition: with chronic use, fentanyl can be detected more than 21 days after the last exposure. And because immunoassays are strictly qualitative, they confirm exposure but cannot quantify concentration, ruling out any assessment of impairment or clinical severity.

Against this backdrop, the evidence on physician interpretation is sobering. In a study by Starrels and colleagues, internal medicine residents scored a mean of just 3.0 out of 7 on an assessment of urine drug test interpretation, yet 56 percent reported confidence in their evaluations. Confidence did not track with accuracy: 73 percent of the confident residents scored 3 or lower. Chua and colleagues documented similar deficits at the bedside, finding that clinicians documented an interpretation for only 55 percent of UDT results in outpatient clinics, and that expert toxicologist review identified misinterpretation in 28 percent of those documented cases.

These are not abstract statistics. The authors recount cases from their own practices in which a single misread test caused direct harm. One woman, admitted for an acute illness, had reported faithful adherence to prescribed clonazepam, but when her urine test came back negative, the inpatient team abruptly stopped the medication, precipitating benzodiazepine withdrawal and a panic attack. Another patient arrived in the intensive care unit with respiratory failure from a synthetic opioid overdose, yet a negative opiate immunoassay sent the team searching for other causes and delayed definitive treatment. A third patient presenting with chest pain tested falsely positive for amphetamines because of prescribed trazodone, and his pain was initially misattributed to stimulant use, hindering timely diagnosis. In each case, premature diagnostic closure built on one misinterpreted test led to preventable injury.

The authors’ first remedy is educational. They call for a formal urine drug testing and medical toxicology curriculum woven into internal medicine residency training, covering consent before ordering, the distinction between immunoassays and the more sensitive and specific technique of mass spectrometry, individual drug metabolism and detection windows, and the common false positives and false negatives that arise from an increasingly synthetic drug supply. Clinicians should know which targeted and confirmatory assays exist beyond the standard panel and when to deploy them, and they must learn to recognize substance-specific toxidromes so that clinical presentation, not a presumptive lab value, drives initial management. Greater diagnostic fluency, they argue, would reduce over-reliance on the UDT and prompt earlier consultation with toxicology or addiction medicine specialists while confirmatory results are pending. Some curricular components have been described before, but they have never been integrated into standardized training in internal medicine or the other specialties that order these tests most often.

Education alone, however, cannot compensate for assays frozen in time. The regulatory lag is stark: although fentanyl became the leading driver of opioid overdose mortality by the early 2010s, a CLIA-waived point-of-care fentanyl immunoassay usable at the bedside without specialized laboratory infrastructure did not become available until 2023, a full decade later, and availability remains limited in many health systems. Standard benzodiazepine panels still fail to detect the metabolites of the most commonly encountered compounds. No FDA-cleared test exists for xylazine, the adulterant associated with severe wounds, nor for medetomidine, which can trigger a severe withdrawal syndrome of abrupt onset. The authors urge expanded access to timely, in-house mass spectrometry, which can query a far wider range of substances and adulterants, deliver quantitative drug levels, and resolve both false positives and false negatives on screening immunoassays. Today’s send-out confirmatory processes, they note, can take days, an eternity when treatment decisions hang in the balance.

The viewpoint closes with a warning that misreading a urine drug test is never a benign error. It shapes diagnoses, steers clinical decisions, and compounds the stigma already borne by patients with substance use disorders, a population for whom a suspicious result can mean the difference between compassionate care and dismissal. While efforts to curb unnecessary testing have gained ground in addiction medicine, urine drug testing remains deeply embedded in general medicine largely without the interpretive scaffolding applied to other tests. The implicit promise attached to every test order, the authors conclude, deserves more than current practice delivers, and closing that gap through formalized residency education and modernized assays is, they write, long overdue.

Subject of Research: Interpretation and limitations of urine drug testing in clinical medicine

Article Title: Closing the Interpretive Gap in Urine Drug Testing: A Call for Education and Assay Modernization

Article References: Kee, D. P., Buyske, J. J., & Thakrar, A. P. (2026). Closing the Interpretive Gap in Urine Drug Testing: A Call for Education and Assay Modernization. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10919-0

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10919-0

Keywords: urine drug testing, immunoassay, false positives, false negatives, fentanyl, toxicology, medical education, mass spectrometry, substance use disorder, benzodiazepines, opioid use disorder, drug screening

Buprenorphine is one of three drugs approved by the US Food and Drug Administration for long-term treatment of opioid use disorder, and it is widely regarded as among the most effective and accessible options. The medication works by reducing cravings and easing withdrawal symptoms, which in turn lowers the risk of overdose. It occupies opioid receptors in the brain in a way that blunts the euphoric effects of other opioids while preventing the physical agony of withdrawal, allowing patients to stabilize their lives and remain engaged in care. Unlike some other treatments, buprenorphine can now be prescribed in doctor’s offices and pharmacies, following a December 2025 law intended to expand access, a shift that matters enormously as fentanyl, which is up to 50 times stronger than heroin, continues to drive the opioid overdose epidemic across the United States.

Pregnancy, however, fundamentally changes how the body handles this medication. Physical and hormonal changes accelerate the metabolization of buprenorphine in pregnant patients, meaning that higher doses are often required for them to avoid withdrawal. This is not a marginal effect: data suggest that up to 90 percent of pregnant women with opioid use disorder require higher doses of the drug. The problem is compounded by the fentanyl era, since increased doses are often necessary even for people who are not pregnant to adequately counteract the potency of illicit synthetic opioids. A typical daily dose of buprenorphine administered under the tongue begins at 2 to 4 milligrams, with the standard target dosage reaching 16 to 24 milligrams, though some patients can benefit from doses up to 32 milligrams.

Despite a growing body of research supporting increased dosages as clinically needed, buprenorphine treatment during pregnancy remains inconsistent, and patients frequently receive inadequate amounts of the medication. Clinical guidelines on dosing for pregnant and postpartum patients are vague and offer little direction on dose adjustment. State Medicaid policies often go further still, capping doses in ways that are not grounded in the evidence. In some states, pregnancy guidance around buprenorphine includes language that implies dose minimization should be the goal, an approach that contradicts decades of evidence about the clinical needs of pregnant patients with opioid use disorder.

Dr. Morgan, a research assistant professor of health law, policy and management at Boston University School of Public Health, has built his career around the opioid overdose epidemic and the question of how to improve access to and retention on medications for opioid use disorder. He argues that the gap between what the evidence shows and what policy allows is both wide and consequential. Pregnant women generally metabolize drugs differently than non-pregnant individuals due to the profound physiological changes of gestation, and the failure to adjust dosing accordingly can push patients into withdrawal, a condition that carries serious risks for both mother and fetus and that frequently drives people back to illicit opioid use.

Dr. Leech, an assistant professor of health policy at Vanderbilt University School of Medicine, points to a phenomenon known as therapeutic inertia as a key driver of dangerous underdosing. In pregnancy, clinical uncertainty and concerns about fetal safety can make clinicians reluctant to increase medication doses even when the evidence supports doing so. The result is a system in which pregnant patients may be left under-treated at precisely the moment when stable, sustained treatment matters most, both for their own health and for the health of their babies. Her work focuses on how coverage decisions and policy design shape real-world treatment patterns and outcomes.

The new study will concentrate on pregnant women covered by Medicaid, a population that is central to this public health challenge. State Medicaid programs cover more than 80 percent of pregnant women with opioid use disorder in the United States, which makes Medicaid dosing policies a decisive lever in whether these patients receive adequate care. Yet many Medicaid programs cap daily dosages of buprenorphine, and some states actively discourage physicians from increasing the dosage during a patient’s pregnancy. The researchers will collaborate with investigators from Boston Medical Center to assess national and state-level differences in buprenorphine dosing between pregnant and non-pregnant women with opioid use disorder, examining how dosing patterns have evolved over time and in response to the spread of fentanyl.

Beyond documenting these patterns, the team will examine the effectiveness of different buprenorphine dosage thresholds and how those dosages advance or inhibit sustained treatment. Retention in treatment is one of the most important predictors of outcomes in opioid use disorder, since patients who discontinue medication face sharply elevated risks of relapse and overdose. Understanding whether higher doses keep pregnant patients engaged in care longer, and whether inadequate doses push them toward treatment discontinuation, could reshape clinical practice and coverage policy alike. The researchers will also estimate the long-term health and economic consequences of suboptimal dosing by applying a decision analytic model capable of projecting multiple outcomes among pregnant and postpartum women with opioid use disorder, including treatment discontinuation, postpartum treatment continuation, overdose, infant outcomes, life expectancy, and healthcare utilization, as well as the cost-effectiveness of restricting or increasing Medicaid dosing limits.

Decision analytic modeling occupies a distinctive niche in health services research because it allows investigators to quantify outcomes that would be infeasible or unethical to assess in clinical trials. As Dr. Leech explains, the approach can leverage existing evidence on dosing effects to project outcomes such as maternal and infant lives lost and the long-term costs of untreated opioid use disorder or suboptimal care, providing a rigorous method for comparing the tradeoffs of different coverage decisions. Rather than waiting years for observational data to accumulate, policymakers could use these projections to weigh the consequences of dose caps against the benefits of more generous dosing thresholds, with estimates spanning both health effects and budget impacts.

For the research team, the ultimate ambition is to translate a technical dosing question into a policy and ethical imperative. By demonstrating that higher buprenorphine dosing during pregnancy improves maternal and infant outcomes and is cost-effective, Dr. Morgan and Dr. Leech hope to give state Medicaid programs and clinical guideline writers the evidence they need to abandon dose minimization policies and embrace dosing strategies grounded in the realities of pregnancy metabolism and the fentanyl-dominated drug supply. If successful, the five-year project could help ensure that one of the most effective tools against the opioid epidemic finally works as well for pregnant women as it does for everyone else, turning a preventable source of maternal and infant harm into an opportunity for meaningful public health gains.

Subject of Research: Effectiveness and health-economic consequences of higher-dosage buprenorphine treatment for pregnant women with opioid use disorder

Article Title: Professors receive $3.7 million NIH grant to study effectiveness of higher-dosage buprenorphine among pregnant women with opioid use disorder

Article References: Professors receive $3.7 million NIH grant to study effectiveness of higher-dosage buprenorphine among pregnant women with opioid use disorder. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: buprenorphine, opioid use disorder, pregnancy, Medicaid, NIH grant, maternal health, fentanyl, health policy, decision analytic modeling, overdose prevention, Boston University, Vanderbilt University

The clinical stakes are laid bare in the opening case. Mr. Warren, hospitalized with bacteremia caused by resistant gram-negative bacteria, repeatedly requested discharge because standard withdrawal treatments were not controlling his symptoms. His care team started with methadone, his preferred medication for opioid use disorder, along with clonidine and symptomatic adjuncts. When those measures failed and he again moved to leave, the team turned to high doses of intravenous hydromorphone, delivered through a patient-controlled analgesia pump that allowed smaller, more frequent doses with lockout periods. The objective signs of withdrawal, including elevated heart rate, dilated pupils, yawning, tremors, goosebumps, vomiting, diarrhea, and sweating, all ceased. What remained were cravings, which the author identifies as a cornerstone symptom of withdrawal and the predominant driver of the patient’s urge to leave.

The central argument of the viewpoint is that opioid withdrawal, including uncontrolled cravings, should be treated as an acute, life-threatening illness requiring prompt management, just as sepsis or diabetic ketoacidosis would be. Rose contends that the historical framing of withdrawal as uncomfortable but benign has bred complacency. In reality, untreated or undertreated withdrawal is a common cause of premature hospital discharge and a rapid return to fentanyl use, which acutely raises mortality both through overdose and through complications of foregone medical care. Avoidance of withdrawal, he notes, is also a major reason patients with opioid use disorder continue to use opioids in the first place.

Fentanyl has magnified these dangers. As the dominant non-prescribed opioid across the United States, it carries a markedly higher overdose risk than heroin or prescription opioids. Its brief duration of action increases injection frequency, compounding risks of infectious complications such as endocarditis and viral hepatitis. Its potency also raises patient tolerance, and its accumulation in tissues prolongs withdrawal, often making traditional methadone titrations unbearable and increasing the risk of precipitated withdrawal when buprenorphine is initiated. Clinicians are therefore increasingly confronting hospitalized patients with severe illness whose withdrawal and cravings cannot be controlled by conventional protocols alone.

The pharmacological rationale for intravenous therapy follows established practice in other acute conditions. For pathologies ranging from sepsis to heart failure to diabetic ketoacidosis, intravenous medications are initially required to achieve faster clinical improvement and offer superior titratability. The same logic applies to other withdrawal syndromes, such as alcohol withdrawal, and to opioid use for acute pain. Intravenous opioids produce a rapid rise in drug concentrations that facilitates swift symptomatic relief, while their short half-lives reduce the risk of accumulation. Patient-controlled analgesia pumps, which require active patient participation and enforce lockout intervals, can safely deliver the large morphine-equivalent doses demanded by patients with especially high fentanyl-driven tolerances while granting them a measure of autonomy over their own treatment.

Short-acting opioids, whether intravenous or oral, already have a recognized adjunctive role in the literature. They can fill residual opioid agonism deficits during methadone titrations. During buprenorphine initiation, they can be used for symptom control while fentanyl clears from the body, alongside buprenorphine during low-dose initiations, or to treat precipitated withdrawal if it occurs. This adjunctive use is described as an increasingly accepted harm reduction practice. What remains undefined, and what the viewpoint seeks to address, is the specific role of the intravenous route, whose absence from formal guidance has produced uncertain and inconsistent use across hospitals.

A crucial element of the argument is the assessment of risk. Clinicians rightly worry that the association between receiving opioids and relief from distress or cravings could reinforce, rather than reverse, the learned behavior that opioids are a solution to stressors. Faster time to peak effect, a hallmark of intravenous administration, is known to increase this reinforcing potential. However, Rose argues that for hospitalized patients with severe opioid use disorder, fentanyl use, and uncontrolled withdrawal, the risk of worsening the disorder is low while the benefit of controlling symptoms, thereby facilitating ongoing medical care including addiction treatment, is high. As time and treatment suppress withdrawal and cravings and the acute medical illness improves, the risk-benefit calculus reverses, and short-acting opioids should be discontinued.

The viewpoint is emphatic that intravenous opioids are never a substitute for evidence-based treatment. Medications for opioid use disorder should be recommended to all patients and serve as the backbone of withdrawal management, with buprenorphine or methadone identified as the most effective treatments even for patients uninterested in continuing them after discharge. Alpha-2 agonists such as clonidine or lofexidine should be first-line adjunctive therapies unless contraindicated. Symptomatic treatment with anxiolytics like hydroxyzine, antiemetics like ondansetron, antispasmodics like dicyclomine, antidiarrheals like loperamide, and non-opioid pain medications such as NSAIDs should also be deployed as needed. Short-acting opioids enter the picture only for patients with residual symptoms despite these measures, or in rare instances where patients decline buprenorphine and methadone entirely and the medications are used to facilitate hospital-based care.

Route selection and expectation setting form the practical core of the proposed guidance. Because the reinforcing risk of rapid-onset opioids is amplified with prolonged use, oral opioids should be prioritized once initial withdrawal symptoms have improved and effective doses have been identified. This transition also smooths drug exposures, offering more consistent symptom control throughout the day. Plans to move from intravenous to oral therapy and eventually to discontinue short-acting opioids altogether should be established with patients early. Once patients reach therapeutic buprenorphine doses, typically 16 to 24 milligrams daily, short-acting opioids should no longer be required. Methadone initiation is typically slower, and patients should understand that short-acting opioids will be tapered as methadone is increased, a process that growing evidence suggests can be expedited through more rapid titration schedules.

The case concludes with hard-won but partial success. Mr. Warren’s symptoms improved on the patient-controlled pump, which was transitioned to oral therapy over subsequent days. As methadone was uptitrated, the short-acting opioids were tapered and eventually discontinued. He remained hospitalized for fourteen days of intravenous antibiotics, his first full treatment course in years. On the eve of transfer to rehabilitation, he again packed his bag and requested discharge, and this time no argument could dissuade him. He left with naloxone, a month’s supply of his medications, and a handshake. His infection was cured and he was alive, but not yet ready for recovery. That outcome, the viewpoint suggests, is precisely the point: intravenous opioids did not cure addiction, but they kept a critically ill patient in the hospital long enough to cure the infection that would otherwise have killed him, and they bought time that conventional withdrawal management alone could not.

Subject of Research: Use of intravenous opioids to manage opioid withdrawal in hospitalized patients with opioid use disorder

Article Title: The Role of IV Opioids for Opioid Withdrawal in Hospitalized Patients

Article References: Rose, M. R. (2026). The Role of IV Opioids for Opioid Withdrawal in Hospitalized Patients. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10856-y

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10856-y

Keywords: opioid withdrawal, intravenous opioids, opioid use disorder, fentanyl, methadone, buprenorphine, hospitalized patients, harm reduction, patient-controlled analgesia, medications for opioid use disorder, withdrawal management, internal medicine

The review, conducted by researchers at the Universidade Federal do Rio Grande do Sul in Brazil, searched PubMed/Medline, Scielo and Google Scholar for articles and technical notes published between 2020 and 2024. From an initial pool of 108 works, 41 studies were included in the final analysis. The authors note that the United Nations Office on Drugs and Crime had recorded more than 120 opioid receptor agonists by 2024, divided into five subgroups: fentanyl analogues, U-series substances, nitazenes, piperazines and a miscellaneous category. Nitazenes stand out within this crowded field because of the sheer affinity of some analogues for the µ-opioid receptor. The first fatal case involving isotonitazene, one of the most notorious members of the family, was reported in the United States in August 2019, only months after the compound first appeared on the recreational market. Since then, metonitazene, butonitazene, flunitazene, etodesnitazene, protonitazene and N-pyrrolidinoetonitazene have all been identified in forensic casework, and between 2019 and 2025 a total of 32 nitazene analogues were reported by 36 countries.

What makes the current wave of nitazene activity particularly hazardous is the way these substances reach consumers. They are rarely sold as standalone products. Instead, they are frequently detected as adulterants in heroin, benzodiazepines, synthetic cannabinoids and even cocaine, often without the knowledge of the people who buy them. This adulteration broadens the population at risk far beyond habitual opioid users. In Brazil, a country where opioid misuse had historically been considered statistically insignificant, the arrival of nitazenes came through an unexpected channel: herbal smoking blends sold as synthetic cannabinoids. An analysis of 140 opioid samples seized by São Paulo state police over roughly one year found that 95 percent contained nitazene analogues, with metonitazene present in 72 percent of the nitazene-positive samples. In most of these cases the compounds appeared in combination with other drugs, meaning users were inhaling a potent opioid hidden inside a product they believed contained something else entirely.

The chemistry behind this potency is instructive. Nitazene analogues share a benzimidazole nucleus linked to an amine group, and small modifications to the side chains produce compounds with markedly different pharmacological profiles. Etonitazene, first synthesized in 1957, proved in animal models to be between 100 and 1000 times more potent than morphine, making it the most powerful compound of the 2-benzylbenzimidazole subclass. Isotonitazene ranked second in potency, followed by protonitazene, metonitazene and butonitazene. The electron-withdrawing nitro group at the 5-position of the ring, the structural feature that gives the nitazenes their name, reduces the basicity of the heteroaromatic ring and appears central to receptor binding. The basic properties of these molecules generally dominate over their acidic ones, owing to two basic moieties: the benzimidazole ring and a tertiary amine in the side chain. These subtle structural differences translate into dramatic differences in how strongly each compound activates opioid receptors and how long it stays bound to them.

Once inside the body, nitazene analogues follow a metabolic route that creates its own set of problems. Biotransformation is mediated primarily by cytochrome P450 enzymes in the liver, particularly the CYP2D6, CYP2B6 and CYP2C8 isoforms. Phase I metabolism oxidizes the parent compounds, introducing reactive and polar functional groups, while phase II conjugation adds glucuronides and sulfates to facilitate urinary excretion. Crucially, some of the metabolites generated along the way are pharmacologically active in their own right. The main urinary metabolite of isotonitazene, N-desethyl-isotonitazene, is actually more potent than the parent drug and has itself appeared for sale on the drug market. Metabolite profiling shows that the O-desalkyl metabolites of isotonitazene and metonitazene are the same molecule, complicating the interpretation of toxicological results, and in silico analysis of etazene suggests it is three times more lipophilic than morphine, crosses the blood-brain barrier readily and inhibits several major CYP enzymes. Genetic variation in CYP450 activity means metabolism can differ substantially between individuals, adding further unpredictability to overdose risk.

Clinically, nitazene exposure produces the effects expected of powerful opioids: euphoria, pain relief and relaxation, followed by drowsiness, dizziness, nausea, constipation and dry mouth. The life-threatening effect is respiratory depression, which can progress to cardiac arrest. Prolonged exposure leads to tolerance, dependence and a characteristic withdrawal syndrome that begins with anxiety, drug craving and lacrimation before escalating to tremors, muscle pain, tachycardia, hypertension and gastrointestinal distress. What distinguishes nitazenes from earlier opioid threats is the difficulty of reversing their overdoses with naloxone, the standard opioid antidote. Laboratory work suggests that nitazenes and fentanyl analogues dissociate slowly from the µ-opioid receptor, reducing naloxone sensitivity. A systematic review found that nitazene overdoses typically required naloxone doses in the range of 1 to 6 milligrams, compared with the 0.4 to 0.8 milligrams usually sufficient for heroin. In one Brazilian clinical case involving N-pyrrolidinoprotonitazene, a patient with a blood concentration of 3.0 nanograms per milliliter required three ampoules of naloxone, equivalent to 1.2 milligrams, before respiratory function improved. The short half-life of naloxone relative to these synthetic opioids also means respiratory depression can relapse, demanding repeated dosing and sustained monitoring.

Detecting nitazenes in biological samples presents a formidable analytical challenge. Because these compounds are so potent, they are consumed at microgram doses and clear the body rapidly, so timely sampling and highly sensitive instruments are essential. Liquid chromatography coupled with tandem mass spectrometry has become the method of choice, typically using whole blood as the primary matrix and liquid-liquid extraction for sample preparation. Related techniques, including GC-MS and LC-QTOF-MS, allow detailed chemical differentiation between analogues. Forensic scientists emphasize that robust documentation of exposure requires detecting the parent compound alongside N-desethyl, O-desalkyl and N-desethyl-O-desalkyl biomarkers, since metabolites are often more abundant than the original drug. Adding to the confusion, illicit production by the original synthetic route can generate positional isomer impurities that confound analytical interpretation. The review also highlights a promising harm-reduction tool: nitazene test strips, a lateral flow immunoassay commercially available since early 2024 and calibrated against isotonitazene. However, a Belgian laboratory evaluation found the strips failed to detect two analogues, metodesnitazene and etodesnitazene, even at high concentrations, underscoring how quickly the market evolves beyond the tools designed to monitor it.

The regulatory response has been uneven. Brazil formally controlled metonitazene in 2023 and has since listed ten more analogues, while its national rapid alert system for new psychoactive substances was only permanently formalized in early 2025. In a potentially significant shift, China introduced generic control of the entire nitazene structure in June 2025, meaning any new analogue containing the core scaffold is now illegal. The downstream effects on the illicit market remain uncertain, but similar generic controls on fentanyl precursors have previously reshaped supply chains in unpredictable ways. The review’s authors stress that underreporting remains a major obstacle to understanding the true scale of the problem, since many poisonings go unidentified without specialized testing and standardized reporting protocols are still lacking.

The core message from the toxicologists is that health systems must adapt before the crisis deepens. The combination of extreme potency, active metabolites, polysubstance adulteration and naloxone resistance creates a clinical scenario for which many emergency services are not adequately prepared. The authors call for specific intervention protocols, training for health professionals on the risks of synthetic opioids, and urgent advances in toxicokinetic and toxicodynamic research to support detection, treatment and rehabilitation programs. Without that foundation, they warn, public health authorities will continue to underestimate both the prevalence and the lethality of these compounds. As nitazene analogues spread through adulterated drug supplies worldwide, the gap between what users think they are consuming and what is actually in the sample may prove to be the deadliest variable of all.

Subject of Research: Toxicology of emerging nitazene analogue synthetic opioids and their overdose risks

Article Title: Toxicological aspects of emerging nitazene analogues as a new threat to the synthetic drug landscape

Article References: Martins, J. N., dos Santos, B. P., & Arbo, M. D. (2026). Toxicological aspects of emerging nitazene analogues as a new threat to the synthetic drug landscape. Discover Toxicology, 3(1), Article 5. https://doi.org/10.1007/s44339-026-00050-4

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00050-4

Keywords: nitazenes, synthetic opioids, isotonitazene, metonitazene, fentanyl, naloxone, overdose, new psychoactive substances, toxicokinetics, respiratory depression, forensic toxicology, drug detection

Researchers led by Michele M. Easter of the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine, working with colleagues at the Wilson Center for Science and Justice at Duke Law, examined death by distribution prosecutions across all of North Carolina between 2013 and 2024. Their analysis, published in the American Journal of Criminal Justice, drew on court records spanning the state’s 42 prosecutorial districts and 100 counties. The goal was to map how often these charges were filed over time and to identify the district- and county-level characteristics associated with prosecution. The findings point to what the authors call geographic arbitrariness in the application of a law born from the overdose crisis.

The study documented 557 death by distribution court charges statewide over the study period. The trajectory was steep. Although North Carolina first passed a death by distribution statute in 2017, the vast majority of charges, 88 percent, were filed after 2020, when a new version of the legislation took effect. That expansion coincided with the worsening of the fentanyl era, during which both overdose deaths and DD-charging rose together across the state. Cases moved at varying speeds: an examination of case-level court data showed a mean of 155 days between the overdose offense date and the filing of charges, with a median of 121 days and a striking range from zero to 897 days.

A crucial technical detail of the statute shapes who can be swept into its net. Sixty percent of the charges were filed under the least serious form of death by distribution, a felony class that does not require proof of a drug sale, an intent to distribute, or any prior criminal history. In practice, this category could apply to virtually any instance of drug sharing that ends in a fatal overdose, including situations where two people used the same substance together and one did not survive. Because this broadest form dominated the caseload, most of the researchers’ statistical analysis focused on it, and its reach raises the stakes of understanding how charging decisions are actually made.

The core empirical question was whether prosecutions track the underlying public health crisis. They do not, at least not cleanly. Correlations between the number of overdose deaths in a district or county and the number of death by distribution charges were weak. If the law functioned as a direct, proportionate response to overdose mortality, one would expect jurisdictions with more deaths to file more charges. Instead, the pattern was scattered and uneven, with some places generating charges at rates far out of proportion to their overdose burden. One district, comprising Stanly and Montgomery counties, and nine individual counties, including Martin, Carteret, Stanly, Graham, Washington, Polk, Chatham, Northampton, and Pamlico, emerged as high outliers in charges per 1,000 overdose deaths.

To understand what did drive charging, the team built regression models relating death by distribution charging rates to district and county characteristics. The most consistent predictors were population size, racial composition, and poverty. Among the 42 prosecutorial districts, the relationship between racial composition and death by distribution cases was curvilinear and bell-shaped, meaning charges peaked in districts with intermediate racial compositions rather than rising linearly. Among the 100 counties, greater poverty was associated with fewer death by distribution charges after adjusting for population, a counterintuitive finding that complicates any simple narrative about who bears the brunt of these prosecutions.

The practical implication is stark: two people who engage in essentially identical conduct, sharing drugs with a friend who then dies, face radically different legal risks depending on which side of a county or district line they happen to live on. This mirrors a pattern documented in the capital punishment literature, where researchers have shown for decades that the decision to seek the death penalty varies enormously across counties within the same state, an earlier body of work that inspired the title of the North Carolina study. In the context of overdose, however, the stakes extend beyond sentencing disparities to the integrity of public health policy itself.

That is because a substantial body of research suggests death by distribution laws may actively undermine evidence-based responses to substance use disorder. Public health approaches to the overdose crisis depend on people who use drugs calling for help during an emergency, carrying naloxone, and being honest with medical providers and harm reduction workers about what they took. Studies of Good Samaritan overdose laws show that fear of legal consequences suppresses 911-calling behavior among overdose witnesses, and research with incarcerated people has described a deterrence paradox in which removing one supplier from a drug market simply creates a vacancy for the next. Prosecutors and legal scholars have also documented that these statutes often rest on mistaken assumptions about how illicit drug markets work, since many people charged never intended to sell anything and shared doses among equals.

The North Carolina study is careful to frame its findings as a starting point rather than a verdict. The authors note that their work invites conversations about potential alternatives for those who seek justice for people who die from overdose, ranging from restorative justice practices to public health-centered responses that treat overdose as a preventable medical outcome rather than a homicide. They also emphasize that crisis-driven legislation, passed in moments of acute grief and public alarm, often produces laws whose real-world application diverges sharply from their stated aims, a dynamic observed in other domains of American policy. The uneven geography of death by distribution charging documented here offers a statewide, data-driven illustration of that divergence.

What the study ultimately delivers is a map of legal exposure that no one designed and no one defends. A law intended to target predatory suppliers is, in its most commonly used form, reaching people whose culpability may amount to little more than shared drug use, and the likelihood of being charged at all depends on local prosecutorial culture, community demographics, and economic conditions. As more states adopt similar statutes amid the ongoing fentanyl crisis, the North Carolina data provide a template for the questions they should expect: not only whether these laws deter overdose deaths, but whether the decision to transform a tragedy into a homicide case can be justified when it is, in effect, decided by geography.

Subject of Research: Death by distribution prosecutions for fatal drug overdoses across North Carolina

Article Title: Geographic Arbitrariness? Examining Death by Distribution Prosecutions Statewide in North Carolina

Article References: Easter, M. M., Grunberg, R. L., Stenger, M., Bass-Patel, L., Swanson, J. W., & Lee, A. (2026). Geographic Arbitrariness? Examining Death by Distribution Prosecutions Statewide in North Carolina. American Journal of Criminal Justice. https://doi.org/10.1007/s12103-026-09935-x

Image Credits: AI Generated

DOI: 10.1007/s12103-026-09935-x

Keywords: death by distribution, drug-induced homicide, overdose, opioid crisis, fentanyl, prosecution, North Carolina, substance use disorder, geographic disparity, criminal justice, public health, harm reduction

The social-ecological framework, first articulated by developmental psychologist Urie Bronfenbrenner, holds that health decisions are never made in a vacuum. Instead, they emerge from interacting layers of influence: personal beliefs and motivations at the core, surrounded by family and peer networks, then the clinics and neighborhoods where people live, and finally the policies, laws and dominant social attitudes that govern treatment itself. The research team applied a modified version of this model to understand how recently incarcerated patients navigate a treatment landscape that has shifted dramatically in the past five years. Federal regulators have expanded take-home methadone doses, reducing the number of days patients must appear in person at an opioid treatment program, and removed the cap on how many patients a provider may prescribe buprenorphine to. Long-acting injectable buprenorphine has also entered the market, bringing its own barriers of cost and limited clinic availability.

Between March and August 2025, the team conducted semi-structured interviews averaging 50 minutes with adults who had received methadone or buprenorphine during an incarceration in the past year. Participants were recruited through opioid treatment programs, office-based providers and recovery centers across the state, with purposive efforts to balance representation by medication type. The sample, on average, had been released just over five months before the interview, was 37.6 years old on average, and included 16 men and 12 women. Most participants were White and non-Latino. At the time of interview, 25 of the 28 participants were receiving methadone and only three were on buprenorphine, even though most had received methadone during incarceration as well. Interviews were transcribed, coded using template-style thematic analysis with both deductive and inductive codes, and analyzed in NVivo until thematic saturation was achieved.

The first and most personal theme concerned perceived benefits. Participants continued MOUD when they felt it clearly worked — helping them avoid withdrawal, illicit opioid use and reincarceration, three outcomes that participants described as deeply intertwined. Many reported that methadone curbed their cravings more effectively than buprenorphine, a difference that proved decisive. One participant who could not reach a methadone clinic after release discontinued treatment entirely because buprenorphine, though easier to obtain with only monthly provider visits, did not adequately suppress his cravings; he resumed methadone only after moving closer to a clinic. This finding underscores a technical point with major clinical implications: patient preference is not merely about convenience but about pharmacological fit, and when the medication that works best is inaccessible, some patients opt for no medication at all.

Paradoxically, nearly all participants — even those who credited MOUD with stabilizing their recovery — expressed an intention to taper off within the next couple of years. Many described methadone or buprenorphine as a band-aid, a short-term tool rather than a chronic therapy, reflecting what the authors identify as an internalized abstinence narrative. This belief had concrete consequences for treatment selection: some participants rejected long-acting injectable buprenorphine precisely because its monthly dosing removed the daily control that would let them stop when they chose. The researchers argue that distinguishing between patients whose desire to discontinue is clinically congruent and those whose desire is driven by stigma or structural barriers is essential for designing interventions that improve retention during the highest-risk period.

At the interpersonal level, the study found that supportive family involvement was invaluable but rare. A few participants relied on relatives for transportation to daily methadone dosing, a logistical lifeline that made treatment feasible. Far more common was stigma within families, where methadone was perceived as simply swapping one drug for another. Several participants concealed their treatment from loved ones, describing it as embarrassing, and this concealment bred isolation. In one striking account, a participant who had been stable after a previous release — employed, housed, engaged in methadone treatment — stopped the medication because of his mother’s disapproval, relapsed into illicit opioid use, and experienced worsening mental health. Others deliberately shrank their social circles to avoid substance use triggers or exposure. Against this backdrop, many participants emphasized self-reliance, framing their recovery as something they had to accomplish alone, and some even preferred buprenorphine’s relative lack of wraparound services because it demanded less dependence on institutions.

Community and organizational factors proved to be powerful levers of access. Housing proximity to an opioid treatment program, access to a working vehicle, and reliable bus routes determined whether daily methadone dosing was realistic. Free transportation services funded through public insurance helped some participants, but others were unaware of these programs, lost passes, or found multi-bus commutes prohibitive. One woman who had to make lengthy near-daily trips by bus concluded that methadone simply did not work for someone without a car and expressed regret over starting it during incarceration, saying she would prefer a monthly injectable so she would not have to worry about dosing every day. The physical environment around clinics also mattered: visible drug activity near treatment sites triggered discomfort and cravings for some patients, deterring them from clinics even when those clinics were close to home.

Clinic practices themselves shaped treatment trajectories. Participants described anxiety over whether they could receive same-day dosing at community intake, hearsay about waitlists, unclear urine drug screening policies, and fear of missing doses when entering residential programs. Although no participant experienced significant gaps in care after reaching a clinic, the psychological cost of fearing withdrawal was real, and for some it motivated a desire to taper off entirely. One participant, facing a warned urine drug screen from his buprenorphine prescriber shortly after release, chose to stop treatment and continue using before later switching to methadone. These accounts illustrate how restrictive or opaque clinic rules can convert a treatable condition into a cycle of disengagement, use and re-engagement.

At the structural level, the fentanyl-dominant drug supply emerged as a decisive force. Participants who were still using opioids feared precipitated withdrawal if they initiated buprenorphine with fentanyl in their system, rendering buprenorphine and its injectable formulation non-viable options in their eyes. Methadone, by contrast, was seen as robust in the fentanyl era, though a few participants described developing a double habit — concurrent methadone and illicit fentanyl use that pushed their methadone doses upward and left them uncomfortable if either substance was unavailable. Methadone also carried a unique legal advantage: its mandatory counseling satisfied probation requirements for some participants, helping them avoid re-arrest, a benefit no buprenorphine recipient reported. Meanwhile, expanded take-home methadone policies motivated engagement for some, but patients with instability indicators often could not accrue take-homes quickly enough, and the threat of losing privileges after hospitalization or reincarceration discouraged others. Systemic stigma in employment and housing further eroded commitment, with participants questioning whether they could be hired as nurses or in other careers while on methadone.

The authors conclude that MOUD preferences and intentions after incarceration are entangled with multilevel barriers, and that improving retention will require interventions at every layer: pre-release education to counter misinformation and stigma, stronger linkage to MOUD-affirming recovery communities and peer support specialists, transportation solutions, and lower-barrier delivery models including community-based post-release dosing. Peer support specialists were described as helpful by the few participants who encountered them, but their scarcity reflects the slow integration of these roles into treatment systems. Given that discontinuing MOUD sharply elevates overdose risk, particularly when cessation occurs early, the stakes of preference-congruent care could not be higher. This study offers a detailed, patient-centered map of why people leaving incarceration choose, keep or abandon their medications — knowledge the authors say is essential for building treatment systems that keep people alive through the perilous transition home.

Subject of Research: Social-ecological determinants of medication preferences and receipt for opioid use disorder after incarceration

Article Title: Social-ecological factors shape preferences for and receipt of medications to treat opioid use disorder in the post-incarceration period

Article References: Bailey, A., Hughto, J. M., Kelly, P. J., Dunsiger, S. I., & Martin, R. A. (2026). Social-ecological factors shape preferences for and receipt of medications to treat opioid use disorder in the post-incarceration period. SSM – Mental Health, 10, Article 100705. https://doi.org/10.1016/j.ssmmh.2026.100705

Image Credits: AI Generated

DOI: 10.1016/j.ssmmh.2026.100705

Keywords: opioid use disorder, methadone, buprenorphine, post-incarceration, social-ecological model, stigma, overdose risk, fentanyl, opioid treatment programs, peer support, reentry, qualitative research